Fludrocortisone for orthostatic hypotension.

This review evaluates the use of fludrocortisone, a mineralocorticoid, for managing orthostatic hypotension, which is a significant drop in blood pressure upon standing. The review identified 13 studies, including a few small RCTs and observational studies, assessing fludrocortisone mainly in patients with diabetes and Parkinson’s disease. The evidence quality was very low, thus making it uncertain whether fludrocortisone effectively impacts blood pressure or orthostatic symptoms. While some data suggested minimal side effects and potential use for familial dysautonomia without harm, the lack of standardized outcomes and measurements hampers definitive conclusions. There's a call for better research that standardizes methods and broadens disease applicability.